Tenon Medical reports third-quarter 2026 results as revenue reaches $1.4 million
Tenon Medical reported higher third-quarter revenue and gross profit, raised approximately $15.6 million in gross proceeds, repaid its senior convertible notes and launched a 3D-printed lateral screw for its SImmetry®+ system.
Tenon Medical, Inc. (NASDAQ:TNON) reported third-quarter 2026 revenue of $1.4 million, up 22% from $1.2 million in the same quarter of 2025. The medical device company also disclosed financing activity, debt repayment, product development progress and additional patent awards for the period ended September 30, 2026.
Gross profit increased to $1.0 million from $0.8 million a year earlier. Gross margin was 66.3%, compared with 65.9% in the third quarter of 2025.
Tenon said the quarterly revenue increase was mainly related to a higher number of surgical procedures, including continued adoption of the SImmetry®+ SI Joint Fusion System. Revenue for the nine months ended September 30, 2026 was $4.1 million, compared with $2.5 million in the corresponding period of 2025.
Operating expenses were $4.0 million, down from $4.2 million in the prior-year quarter. The company attributed the reduction primarily to lower general and administrative costs and professional service fees. This was partly offset by higher sales and marketing expenses linked to revenue activity and increased research and development spending.
Operating loss improved to $3.1 million from $3.4 million. Net loss, however, was $6.6 million, or $5.39 per share, compared with $3.3 million, or $14.17 per share, in the third quarter of 2025.
Tenon said the higher net loss primarily reflected non-cash items below operating income, including $3.1 million related to warrants issued as inducement consideration and $0.7 million in non-cash interest expense from the amortisation of debt discount on convertible notes.
The company raised approximately $15.6 million in aggregate gross proceeds during the third quarter. The proceeds included a $4.2 million public offering completed on July 1, 2026, a $3.0 million private placement closed on August 31, 2026, and a September 2026 warrant inducement transaction that generated approximately $2.9 million.
Tenon also received approximately $2.8 million from its at-the-market offering programme and approximately $2.7 million from warrant exercises during the quarter.
Cash and cash equivalents stood at $8.3 million as of September 30, 2026, compared with $3.8 million as of December 31, 2025. The company said it repaid its senior convertible notes in full through prepayments made in August and September 2026. The notes had an aggregate principal amount of approximately $5.16 million and were due to mature on September 11, 2026.
Tenon said it had no outstanding debt at the end of the quarter. It also reported regaining compliance with Nasdaq’s minimum stockholders’ equity requirement and minimum bid price requirement. The latter followed a 1-for-35 reverse stock split that took effect on August 10, 2026.
During the quarter, Tenon began the full commercial launch of a 3D-printed lateral screw for its SImmetry®+ SI Joint Fusion System. The company described the device as the first component of a next-generation lateral system.
The launch followed an alpha programme that generated approximately $1.2 million in revenue from late in the fourth quarter of 2025 through the third quarter of 2026.
Tenon also said it had completed the initial alpha cases of its Quickstep™ Decorticator. The device is intended to streamline joint decortication and simplify the SImmetry®+ surgical workflow. The company is targeting full market release in the first quarter of 2027, although that timing remains a company target.
Thomas Batton Jr. joined Tenon as chief revenue officer effective October 1, 2026. The company said it plans to continue expanding its commercial organisation through direct sales representatives and distributor partners.
The U.S. Patent and Trademark Office issued eight new patents to Tenon during 2026, bringing the company’s portfolio to 38 issued U.S. patents. Tenon also reported nine international patents and 31 U.S. and foreign patent applications pending.
The new patents include system and method claims covering the Catamaran® SI Joint Fusion System, according to the company.
For the balance of 2026, President and CEO Steven M. Foster said Tenon’s priorities are expanding physician training and adoption across both platforms, advancing the product pipeline and maintaining discipline on spending.
Tenon cautioned that its forward-looking statements are uncertain and that actual results may differ materially from its assumptions, estimates or expectations. The company identified a need to raise additional capital and substantial doubt about its ability to continue as a going concern among the factors that could affect future outcomes.
Third-quarter 2026 revenue was $1.4 million, while gross profit was $1.0 million and gross margin was 66.3%.
Tenon raised approximately $15.6 million in aggregate gross proceeds and ended the quarter with $8.3 million in cash and cash equivalents.
The company repaid senior convertible notes with an aggregate principal amount of approximately $5.16 million and reported no outstanding debt at quarter-end.
Tenon commercially launched a 3D-printed lateral screw for the SImmetry®+ system and completed initial alpha cases of its Quickstep™ Decorticator.
The company reported eight new U.S. patents in 2026, bringing its portfolio to 38 issued U.S. patents, while also disclosing the need for additional capital and substantial doubt about its ability to continue as a going concern.
Tenon Medical reported its financial results for the third quarter ended September 30, 2026, alongside business updates. The company reported higher revenue and gross profit, raised approximately $15.6 million in aggregate gross proceeds, repaid its senior convertible notes in full and commercially launched the 3D-printed lateral screw for the SImmetry®+ SI Joint Fusion System.
Tenon Medical’s shares trade on Nasdaq under the ticker symbol NASDAQ:TNON.
Tenon Medical reported third-quarter 2026 revenue of $1.4 million, an increase of 22% compared with $1.2 million in the third quarter of 2025. Revenue for the nine months ended September 30, 2026 was $4.1 million, up 66% from $2.5 million in the same period of 2025.
Tenon Medical said the quarterly revenue increase was primarily due to a higher number of surgical procedures, including continued adoption of the SImmetry®+ System. The company also said third-quarter revenue increased 12% sequentially from the second quarter.
Tenon Medical reported gross profit of $1.0 million and a gross margin of 66.3% for the third quarter of 2026, compared with gross profit of $0.8 million and a gross margin of 65.9% in the third quarter of 2025. The company attributed the 0.4 percentage point margin increase primarily to higher revenue absorbing fixed costs within costs of goods sold and improved Catamaran® per-procedure costs following the 510(k) clearance announced on July 2, 2026.
Tenon Medical’s operating loss improved to $3.1 million from $3.4 million in the third quarter of 2025, while operating expenses fell to $4.0 million from $4.2 million. The company attributed the expense reduction primarily to lower general and administrative expenses and professional service fees, partly offset by higher sales and marketing expenses and research and development expenses.
Tenon Medical reported a net loss of $6.6 million, or $5.39 per share, in the third quarter of 2026, compared with a net loss of $3.3 million, or $14.17 per share, in the third quarter of 2025. The company said the increase was primarily attributable to non-cash items below the operating line, including $3.1 million of expense related to warrants issued as inducement consideration and $0.7 million of non-cash interest expense from amortisation of debt discount on convertible notes.
Tenon Medical reported cash and cash equivalents of $8.3 million as of September 30, 2026, compared with $3.8 million as of December 31, 2025. The company said it had no outstanding debt as of quarter-end after repaying its senior convertible notes in full.
Tenon Medical said it raised approximately $15.6 million in total gross proceeds during the third quarter. The proceeds included a $4.2 million public offering completed on July 1, 2026, a $3.0 million private placement closed on August 31, 2026, a warrant inducement transaction in September 2026 for gross proceeds of approximately $2.9 million, approximately $2.8 million from its at-the-market offering programme and approximately $2.7 million from warrant exercises.
Tenon Medical said it repaid its senior convertible notes in full through prepayments made in August and September 2026. The notes had an aggregate principal amount of approximately $5.16 million and were repaid ahead of their September 11, 2026 maturity date.
Tenon Medical commenced the full commercial launch of its 3D-printed lateral screw for the SImmetry®+ SI Joint Fusion System. The company described it as the first component of a next-generation lateral system, following an alpha launch that generated approximately $1.2 million in revenue from late in the fourth quarter of 2025 through the third quarter of 2026.
Tenon Medical said it had completed the initial alpha cases of its Quickstep™ Decorticator and was targeting a full market release in the first quarter of 2027. The company said Quickstep is designed to streamline joint decortication and simplify the SImmetry®+ surgical workflow.
President and CEO Steven M. Foster said Tenon Medical’s priorities for the balance of 2026 were expanding physician training and adoption across both platforms, advancing the product pipeline and maintaining discipline on spending. The company also plans to continue adding to its commercial organisation through direct sales representatives and distributor partners.
Tenon Medical said its forward-looking statements are inherently uncertain and that actual results may differ materially from its assumptions, estimates or expectations. The company identified the need to raise additional capital and substantial doubt about its ability to continue as a going concern among the factors that could affect those outcomes.
Tenon Medical scheduled its earnings conference call for 4:30 p.m. ET, or 1:30 p.m. PT, on November 12, 2026. The company said an audio playback would be available through November 26, 2026, on its Investor Relations website or by telephone replay.